These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 11684212

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.
    Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, Bush A.
    Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668
    [Abstract] [Full Text] [Related]

  • 3. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R, Metcalfe C, Wallis C, Bush A.
    Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
    [Abstract] [Full Text] [Related]

  • 4. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK.
    Am J Respir Crit Care Med; 2002 Aug 01; 166(3):352-5. PubMed ID: 12153969
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M, Dasgupta B, Tomkiewicz RP, Brown NE.
    Am J Respir Crit Care Med; 1997 Jul 01; 156(1):173-7. PubMed ID: 9230743
    [Abstract] [Full Text] [Related]

  • 8. Dornase alfa for cystic fibrosis.
    Yang C, Montgomery M.
    Cochrane Database Syst Rev; 2018 Sep 06; 9(9):CD001127. PubMed ID: 30187450
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dornase alfa for cystic fibrosis.
    Yang C, Chilvers M, Montgomery M, Nolan SJ.
    Cochrane Database Syst Rev; 2016 Apr 04; 4():CD001127. PubMed ID: 27043279
    [Abstract] [Full Text] [Related]

  • 12. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.
    Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C.
    Int J Technol Assess Health Care; 2003 Apr 04; 19(1):71-9. PubMed ID: 12701940
    [Abstract] [Full Text] [Related]

  • 13. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.
    Suri R, Metcalfe C, Wallis C, Bush A.
    Respir Med; 2007 Feb 04; 101(2):254-60. PubMed ID: 16806875
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dornase alfa for cystic fibrosis.
    Jones AP, Wallis C.
    Cochrane Database Syst Rev; 2010 Mar 17; (3):CD001127. PubMed ID: 20238314
    [Abstract] [Full Text] [Related]

  • 19. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
    Tarrant BJ, Le Maitre C, Romero L, Steward R, Button BM, Thompson BR, Holland AE.
    Respirology; 2017 Aug 17; 22(6):1084-1092. PubMed ID: 28397992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.